Lipitor

A cancer drug, daraxonrasib, developed by Revolution Medicine, nearly doubled survival rates for pancreatic cancer, sparking a standing ovation at a conference. The article highlights the U.S. innovation model, the 'Innovation Treadmill,' which balances high drug prices with rapid generic substitution to sustain medical breakthroughs. It contrasts U.S. drug access with European delays and discusses trends like genetic advancements and AI in biotech.